# Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

> **NCT07704684** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 376 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Experimental: Sacubitril/Allisartan and Amlodipine Group
- **DRUG:** Active Comparator: Amlodipine Group

## Key facts

- **NCT ID:** NCT07704684
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-28
- **Primary completion:** 2025-08-26
- **Final completion:** 2025-09-08
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704684, "Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*